Integral Molecular Reaches Antibody License Deal With AstraZeneca For Oncology Therapeutics

Integral Molecular said that it reached an exclusive worldwide antibody license agreement with AstraZeneca (AZN,AZN.L) to develop therapeutics for multiple cancers.

As per the terms of the deal, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of monoclonal antibodies for use in oncology. AstraZeneca will be solely responsible for all research, development, and commercial activities.

The antibodies licensed by AstraZeneca were discovered and characterized using Integral Molecular's platforms designed to yield antibodies against structurally complex membrane proteins.

The MPS Antibody Discovery platform, Lipoparticles, Membrane Proteome Array, and Shotgun Mutagenesis Epitope Mapping technologies were used to generate diverse antibodies with exceptional specificity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT